Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia

Relapses are frequent in the first years following a first episode of schizophrenia (FES), being associated with a higher risk of developing a chronic psychotic disorder, and poor clinical and functional outcomes. The identification and intervention over factors associated with relapses in these ear...

Descripción completa

Detalles Bibliográficos
Autores: Bioque, M, Mezquida, G, Amoretti, S, Garcia-Rizo, C, Lopez-Ilundain, JM, Diaz-Caneja, CM, Zorrilla, I, Mane, A, Rodriguez-Jimenez, R, Corripio, I, Pomarol-Clotet, E, Ibanez, A, Usall, J, Contreras, F, Mas, S, Vazquez-Bourgon, J, Cuesta, MJ, Parellada, M, Gonzalez-Pinto, A, Hidalgo-Figueroa, M, Bernardo, M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p9905
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=9905
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125266761&doi=10.1016%2fj.schres.2022.02.026&partnerID=40&md5=02dcb943eb1285976e60d887fc1c9c45
Access Level:acceso abierto
Palabra clave:Antipsychotics
Cannabis
First-episode psychosis
Relapses
Schizophrenia
Second episodes
id ES_d1f5370cf4dc63259aeb64cae251f8ea
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p9905
network_acronym_str ES
network_name_str España
repository_id_str
spelling Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophreniaBioque, MMezquida, GAmoretti, SGarcia-Rizo, CLopez-Ilundain, JMDiaz-Caneja, CMZorrilla, IMane, ARodriguez-Jimenez, RCorripio, IPomarol-Clotet, EIbanez, AUsall, JContreras, FMas, SVazquez-Bourgon, JCuesta, MJParellada, MGonzalez-Pinto, AHidalgo-Figueroa, MBernardo, MAntipsychoticsCannabisFirst-episode psychosisRelapsesSchizophreniaSecond episodesRelapses are frequent in the first years following a first episode of schizophrenia (FES), being associated with a higher risk of developing a chronic psychotic disorder, and poor clinical and functional outcomes. The identification and intervention over factors associated with relapses in these early phases are timely and relevant.In this study, 119 patients in remission after a FES were closely followed over three years. Participants came from the 2EPS Project, a coordinated, naturalistic, longitudinal study of 15 tertiary centers in Spain. Sociodemographic, clinical, treatment and substance abuse data were analyzed.49.6% of the participants relapsed during the 3-years follow-up. None of the baseline demographic and clinical characteristics analyzed showed a statistically significant association with relapses. 22% of patients that finished the follow-up without relapsing were not taking any antipsychotic. The group that relapsed presented higher mean antipsychotics doses (381.93 vs. 242.29 mg of chlorpromazine equivalent/day, p = 0.028) and higher rates of antipsychotic polytherapy (28.6% vs. 13%, p < 0.001), benzodiazepines use (30.8% vs. 8.5%, p < 0.001), side effects reports (39.2% vs. 25%, p = 0.022), psychological treatment (51.8% vs. 33.9%, p = 0.03), and cannabis consumption (93.2% vs. 56.7%, p < 0.001). Clozapine use was notably higher in the group that reminded in remission (21.7% vs. 8.2%, p < 0.019). These findings may guide clinicians to detect subgroups of patients with higher risk to present a second episode of psychosis, focusing on measures to ensure an adequate treatment or facilitating cannabis use cessation. This study supports future research to identify relapse prevention strategies for patients in early phases of schizophrenia.ELSEVIER2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=9905https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125266761&doi=10.1016%2fj.schres.2022.02.026&partnerID=40&md5=02dcb943eb1285976e60d887fc1c9c45SCHIZOPHRENIA RESEARCHISSN: 09209964ISSNe: 15732509reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p99052026-06-14T12:41:47Z
dc.title.none.fl_str_mv Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia
title Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia
spellingShingle Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia
Bioque, M
Antipsychotics
Cannabis
First-episode psychosis
Relapses
Schizophrenia
Second episodes
title_short Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia
title_full Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia
title_fullStr Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia
title_full_unstemmed Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia
title_sort Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia
dc.creator.none.fl_str_mv Bioque, M
Mezquida, G
Amoretti, S
Garcia-Rizo, C
Lopez-Ilundain, JM
Diaz-Caneja, CM
Zorrilla, I
Mane, A
Rodriguez-Jimenez, R
Corripio, I
Pomarol-Clotet, E
Ibanez, A
Usall, J
Contreras, F
Mas, S
Vazquez-Bourgon, J
Cuesta, MJ
Parellada, M
Gonzalez-Pinto, A
Hidalgo-Figueroa, M
Bernardo, M
author Bioque, M
author_facet Bioque, M
Mezquida, G
Amoretti, S
Garcia-Rizo, C
Lopez-Ilundain, JM
Diaz-Caneja, CM
Zorrilla, I
Mane, A
Rodriguez-Jimenez, R
Corripio, I
Pomarol-Clotet, E
Ibanez, A
Usall, J
Contreras, F
Mas, S
Vazquez-Bourgon, J
Cuesta, MJ
Parellada, M
Gonzalez-Pinto, A
Hidalgo-Figueroa, M
Bernardo, M
author_role author
author2 Mezquida, G
Amoretti, S
Garcia-Rizo, C
Lopez-Ilundain, JM
Diaz-Caneja, CM
Zorrilla, I
Mane, A
Rodriguez-Jimenez, R
Corripio, I
Pomarol-Clotet, E
Ibanez, A
Usall, J
Contreras, F
Mas, S
Vazquez-Bourgon, J
Cuesta, MJ
Parellada, M
Gonzalez-Pinto, A
Hidalgo-Figueroa, M
Bernardo, M
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Antipsychotics
Cannabis
First-episode psychosis
Relapses
Schizophrenia
Second episodes
topic Antipsychotics
Cannabis
First-episode psychosis
Relapses
Schizophrenia
Second episodes
description Relapses are frequent in the first years following a first episode of schizophrenia (FES), being associated with a higher risk of developing a chronic psychotic disorder, and poor clinical and functional outcomes. The identification and intervention over factors associated with relapses in these early phases are timely and relevant.In this study, 119 patients in remission after a FES were closely followed over three years. Participants came from the 2EPS Project, a coordinated, naturalistic, longitudinal study of 15 tertiary centers in Spain. Sociodemographic, clinical, treatment and substance abuse data were analyzed.49.6% of the participants relapsed during the 3-years follow-up. None of the baseline demographic and clinical characteristics analyzed showed a statistically significant association with relapses. 22% of patients that finished the follow-up without relapsing were not taking any antipsychotic. The group that relapsed presented higher mean antipsychotics doses (381.93 vs. 242.29 mg of chlorpromazine equivalent/day, p = 0.028) and higher rates of antipsychotic polytherapy (28.6% vs. 13%, p < 0.001), benzodiazepines use (30.8% vs. 8.5%, p < 0.001), side effects reports (39.2% vs. 25%, p = 0.022), psychological treatment (51.8% vs. 33.9%, p = 0.03), and cannabis consumption (93.2% vs. 56.7%, p < 0.001). Clozapine use was notably higher in the group that reminded in remission (21.7% vs. 8.2%, p < 0.019). These findings may guide clinicians to detect subgroups of patients with higher risk to present a second episode of psychosis, focusing on measures to ensure an adequate treatment or facilitating cannabis use cessation. This study supports future research to identify relapse prevention strategies for patients in early phases of schizophrenia.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=9905
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125266761&doi=10.1016%2fj.schres.2022.02.026&partnerID=40&md5=02dcb943eb1285976e60d887fc1c9c45
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=9905
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125266761&doi=10.1016%2fj.schres.2022.02.026&partnerID=40&md5=02dcb943eb1285976e60d887fc1c9c45
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER
publisher.none.fl_str_mv ELSEVIER
dc.source.none.fl_str_mv SCHIZOPHRENIA RESEARCH
ISSN: 09209964
ISSNe: 15732509
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420308408041472
score 15.811543

Similares en LA Referencia